Drug
TER 286 clinical trials
Also written TLK286 and canfosfamide hydrochloride.
- studies test it
- 12
- open now
- 0
- in phase 3
- 3
- first study started
- 2001
How studies write it
Studies that test it under each name
Brand
Development codes
Other names
Combined with it in one product
Studies by the year they started
11 studies that test it; most in 2002 (3)
| Year | Studies |
|---|---|
| 2001 | 2 |
| 2002 | 3 |
| 2003 | 3 |
| 2004 | 2 |
| 2006 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 9
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 2
Often tested with
Tested in the same studies.
Carboplatin (1) · Paclitaxel (1) · Cisplatin (1) · Gefitinib (1)
Studies
Open first, then newest update. How each study uses TER 286 is read from its arms, and is right about nine times in ten.
Testing it · 12
- Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian CancerTerminatedPhase 3TelikNCT00350948Written as Telcyta
- TLK286 in Treating Patients With Advanced Non-Small Cell Lung CancerCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT00036920Written as canfosfamide hydrochloride
- TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT00022347Written as canfosfamide hydrochloride
- Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung CancerCompletedPhase 1/2TelikNCT00088556Written as TLK286
- TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian CancerCompletedPhase 3TelikNCT00057720Written as TLK286 HCl for injection
- TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian CancerCompletedPhase 1/2TelikNCT00052065Written as TLK286
- TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian CancerCompletedPhase 1/2TelikNCT00051948Written as TLK286
- Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung CancerCompletedPhase 2TelikNCT00040638Written as TLK286
- Phase 2 Study of TLK286 in Metastatic Breast CancerCompletedPhase 2TelikNCT00035841Written as TLK286
- TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)CompletedPhase 1/2TelikNCT00077883Written as TLK286, cisplatin
- Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian CancerCompletedPhase 2TelikNCT00038428Written as TLK286
- Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung CancerCompletedPhase 3TelikNCT00080340Written as TLK286 (Telcyta) HCl for Injection